Ask AI
ProCE Banner Activity

New Developments in Immunotherapy-Based Management of Gastric/GEJ Cancers Across the Disease Continuum

Slideset

The downloadable slideset offers learners the opportunity to study content on the latest advances in immunotherapy-based management of resectable and advanced gastric/gastroesophageal junction (GEJ) cancers.

Released: June 26, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

Bristol Myers Squibb

Target Audience

This activity has been designed to meet the educational needs of medical oncologists and other healthcare professionals involved in the management of patients with gastric/GEJ cancers.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Identify patients with resectable gastric/GEJ cancers likely to benefit from established and emerging perioperative immunotherapy-based regimens

  • Recommend immunotherapy-based regimens for appropriate patients with advanced gastric/GEJ cancers based on current guidelines, data, biomarkers, and patient/disease factors

  • Compare subcutaneous vs intravenous formulations of immunotherapies in terms of logistics and the evidence for efficacy, safety, and quality of life

  • Assess the potential clinical impact of emerging data for novel immunotherapy-based regimens on management of gastric/GEJ cancers